A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo

Trial Profile

A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2012

At a glance

  • Drugs Auriclosene (Primary)
  • Indications Impetigo; Staphylococcal infections; Streptococcal infections
  • Focus Therapeutic Use
  • Sponsors NovaBay Pharmaceuticals
  • Most Recent Events

    • 24 Sep 2012 Results have been presented in a Galderma media release.
    • 17 Sep 2012 Results were published in the International Journal of Clinical and Experimental Pathology (IJCEP), according to a NovaBay media release
    • 09 Jun 2011 Additional source identified and integrated: ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top